Evidence map›Paper›PMID 31010863›Full record

ArticleAntimicrobial agents and chemotherapy2019

Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole.

Benjamin Lima, Sandra Bodeau, Marie-Charlotte Quinton, Cyril Leven, Anne-Sophie Lemaire-Hurtel, Youssef Bennis

Open access · bronzeAbstract readValidation Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Benjamin LimaLaboratory of Pharmacology and Toxicology, Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France.
Sandra BodeauLaboratory of Pharmacology and Toxicology, Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France.
Marie-Charlotte QuintonLaboratory of Pharmacology and Toxicology, Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France.
Cyril LevenLaboratory of Pharmacology and Toxicology, Brest University Hospital, Brest, France.
Anne-Sophie Lemaire-HurtelLaboratory of Pharmacology and Toxicology, Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France.
Youssef BennisLaboratory of Pharmacology and Toxicology, Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France bennis.youssef@chu-amiens.fr.
Centre Hospitalier Universitaire Amiens-Picardie · FRCentre Hospitalier Régional Universitaire de Brest · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceftobiprole is a fifth-generation cephalosporin approved for the treatment of pneumonia, with a broad antibacterial spectrum, including potent activity against methicillin-resistant

Indexed as

AgedAnti-Bacterial AgentsCalibrationCephalosporinsChromatography, High Pressure LiquidDrug MonitoringFemaleHumansMaleSeizuresAnti-Bacterial AgentsceftobiproleCephalosporinscephalosporinMRSAneurotoxicitypneumoniatherapeutic drug monitoring

Identifiers

PMID31010863
PMCPMC6591631
OpenAlexW2941915229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.